Niagen Bioscience names Abhijit Kale senior director of global external research

Niagen Bioscience, Inc.

Niagen Bioscience, Inc.

NAGE

0.00
  • Niagen Bioscience named Abhijit Kale as senior director of global external research, effective July 20, 2026.
  • Kale will run the Niagen Research Program, steering external academic and clinical collaborations, shaping research strategy in NAD+ biology.
  • He was most recently a scientific review officer at Hevolution Foundation, reviewing 600+ proposals tied to a USD 1 billion longevity portfolio.
  • Earlier roles included leadership posts at Buck Institute for Research on Aging, Deciduous Therapeutics, LevitasBio.
  • The program supports 175+ active or developing studies, with 45+ peer-reviewed published clinical studies on Niagen.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607160832BIZWIRE_USPR_____20260716_BW002772) on July 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.